Skip to content
Offset.health

Methodology

So you can judge how solid the ranking is, the calculation is laid open here. No statistical prediction model and no language model — a hand-curated database and a disclosed weighting by evidence grade (A 1.0 · B 0.8 · C 0.6 · D 0.4) that you can recompute here.

Where the numbers come from

Every effect row is entered by hand from the published literature, with range, latency, evidence grade and source. No entry is generated or estimated at runtime. Where a figure is uncertain, a weak evidence grade sits next to it, and where no curated figure exists yet, the entry is marked as an unconfirmed placeholder.

The catalogue in figures, counted from the same database this page serves.

Markers
28
Measures
42
Effect rows
221
Sources
225

Evidence grades

The evidence grade describes how well the effect on the lab value is established. It says nothing about whether your clinical outcome changes with it. That sits separately in the outcome column.

Evidence grade A
Several randomised trials or meta-analyses pointing the same way
Evidence grade B
Individual randomised trials or consistent observational data
Evidence grade C
Small or methodologically limited studies, result not settled
Evidence grade D
Mechanistic reasoning or expert opinion, little direct data

How the ordering works

For each measure, one row counts per marker you entered. The contribution grows with how far your value sits from the target range, with the point estimate against the largest known effect in the same unit, and with the evidence grade. Rows without a number keep a neutral size. Markers with no established treatment direction count with weight 0 and stay visible.

Evidence-grade weighting exactly as it stands in the code: A counts 1.0, B 0.8, C 0.5, D 0.3. The marker's urgency tier (1, 0.6, 0.3, 0.05) is applied as well. That lets you recompute any ordering here.

Big levers and small dials share one list. The order follows the evidence, not the category. A poor trade, where the cost sits on a more important marker, is shown in its own section.

Weight reduction drops out of the ranking when height and weight yield a BMI below 18.5. Without those figures the lever stays visible.

Whether an edge is benefit or cost follows from the effect direction and the marker's desirable direction. Markers without an established treatment direction (HDL, hs-CRP, homocysteine, vitamin D, total cholesterol) stay informational — never green progress. A row with direction none is a finding, not an empty cell.

Hidden raisers and prescription context explain a high value. They are for orientation, not lifestyle advice in the ranking.

Both sides stay on the card

The order follows benefit minus cost. On the card the two sides stay separate, rather than collapsing into one combined number. A poor trade goes in its own section. Whether an added purine load matters to you depends on your uric acid, your kidney function and your history of gout.

Food alternatives

The search compares curated foods in the same class using recorded nutrients per 100 g. Suggestions are not a diagnosis. Composition comes from the German Nutrient Database BLS 4.0; purines come from the free USDA/ODS-NIH purine database (which includes Kaneko 2014). Qualitative reasons such as live cultures or a preparation are editorial notes, not effect rows.

How the calculation runs technically

When the page loads, the server delivers the anonymous effect database. Your values stay in a variable in the browser and are combined with that database there. Without an account they never flow back into a request. With an account the browser stores the history as ciphertext; plaintext figures are not in the database. The values are also absent from the address bar.

What we count

There is no tracking and no cookie banner, because there is no reason for one. To see whether the entry point works, we count three events. All that is stored per event and day is one number: how often it happened.

  • Form started: someone entered a value or had a report read in.
  • PDF read: a report was parsed in the browser. The file itself never leaves your device.
  • Result seen: the assessment was displayed.

No lab value, no marker, no IP address and no identifier goes into these counters. So that one visit does not count several times, the browser remembers the event for that tab. We cannot tell from this who you are or what your report says.

Markers and target ranges

The recorded target ranges with their source. Laboratory-specific reference ranges may differ; the range printed on your own report always takes precedence.

MarkerUnitTarget rangeFavourable directionSource
Triglyceridesmg/dL / mmol/L< 150lower2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
HDL cholesterolmg/dL / mmol/L> 40no established direction10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
Apolipoprotein Bmg/dL / g/L< 100lower2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
LDL cholesterolmg/dL / mmol/L< 100lower2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Fasting glucosemg/dL / mmol/L< 100lower2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2025
HbA1c%< 5.7lower2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026
Fasting insulinµIU/mL / pmol/L< 10.0lowerHomeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in manUnconfirmed placeholder
HOMA-IRGlucose × Insulin ÷ 405index—lower—
Ferritinng/mL / µg/L15–200in rangeWHO guideline on use of ferritin concentrations to assess iron status in individuals and populations
Uric acidmg/dL / µmol/L< 6.0lower2020 American College of Rheumatology Guideline for the Management of Gout
Creatininemg/dL / µmol/L< 1.20lowerKDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
Cystatin Cmg/L< 1.00lowerKDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
eGFR (creatinine)mL/min> 60higherKDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
eGFR (cystatin C)mL/min> 60higherKDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
egfr-discrepancy%-30–30in rangeDiscordance in Creatinine- and Cystatin C-Based eGFR and Clinical Outcomes: A Meta-Analysis
Alanine aminotransferaseU/L< 33lowerACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries
Aspartate aminotransferaseU/L< 40lowerACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries
Gamma-glutamyltransferaseU/L< 40lowerCommon reference intervals for aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT) in serum: results from an IFCC multicenter study
Platelet count10⁹/L150–400in rangeAge- and sex-based ranges of platelet count and cause-specific mortality risk in an adult general population: prospective findings from the Moli-sani study
fib-4index< 1.30lowerAASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Homocysteineµmol/L< 15.0no established directionHyperhomocysteinemia and Disease - Is 10 umol/L a Suitable New Threshold Limit?
high-sensitivity CRPmg/L< 2.0no established direction10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
25-OH vitamin Dng/mL / nmol/L> 20no established directionVitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline
Systolic blood pressuremmHg< 130lower2024 ESC Guidelines for the management of elevated blood pressure and hypertension
Diastolic blood pressuremmHg< 80lower2025 AHA/ACC and multisociety Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults

Limits

  • All ranges come from group averages. Within a single study, individual responses run from far stronger to none at all.
  • The ordering uses the point estimate in the marker's own unit. Where no number exists, the row stays visible and counts with a neutral size.
  • Several measures do not add up cleanly in reality. We therefore show them individually and never as a sum.
  • Medication, pre-existing conditions, pregnancy, thyroid function and alcohol consumption change the picture considerably and are not included here.
  • A single lab value is a point in time with measurement scatter, not a state. Triglycerides in particular react strongly to the last meal.

What has changed

When we change something substantial in the database or in the presentation, it is listed here. Same log as on the home page.

  1. 2026-10

    Ranking uses the literature point estimate. Rows without a settled size stay visible and do not count. HDL, hs-CRP, homocysteine and vitamin D stay blue, not as progress.

  2. 2026-09

    Borderline badges removed. Study spans instead of point forecasts. Reporting without an account. FIB-4 and eGFR discrepancy taken out of the consumer product.

  3. 2026-08

    Consolidated-3 import: lifestyle levers, hidden raisers and prescription context with sources.